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INTRODUCTION 
The metabolic syndrome is one of the major public health issues of this 
century. It is a constellation of physical conditions and metabolic abnormalities, 
commonly occurring together, that increases an individual's risk for development of 
type 2 diabetes mellitus and cardiovascular disease. If the current trend continues, 
the premature deaths and disabilities resulting from these conditions will increase 
the financial burden in developing countries. 
        Several expert groups have attempted to define the diagnostic criteria 
for the metabolic syndrome. In 1998, the World Health Organization (WHO) 
proposed a formal definition of the metabolic syndrome; according to this, a person 
must have either glucose intolerance or insulin resistance along with two of the 
following four criteria: central obesity, hypertension, dyslipidemia, and albuminuria. 
In 2001, the National Cholesterol Education Program Adult Treatment Panel III 
(NCEP ATP III)(4) provided a new definition for the metabolic syndrome, according 
to which a person must have three of the following five abnormalities: abdominal 
adiposity, hypertension, hypertriglyceridemia, low high-density lipoprotein 
cholesterol, and elevated fasting glucose. Based on the definitions of NCEP ATP 
III, a cross-sectional study conducted by the Third National Health and Nutrition 
Examination Survey in a US population found that the prevalence of the syndrome 
was 25% among white Americans; the prevalence was 44% among those 50 years 
and older.  
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More recent estimates of the prevalence of the metabolic syndrome ranged 
from 21.3-32.8% among the participants in the Framingham Offspring Study and 
the San Antonio Heart Study (6). Moreover, a recent study in patients with 
established coronary artery disease or stroke showed that the prevalence of the 
metabolic syndrome correlated with the extent of vascular damage. Little is known 
about the prevalence of the metabolic syndrome in patients with acute coronary 
syndrome, particularly in South-East Asians. There is also limited information 
available on the impact of the metabolic syndrome on hospital outcomes after 
presentation for an acute myocardial infarction (AMI) in South-East Asians. 
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REVIEW OF LITERATURE 
THE METABOLIC SYNDROME:  
In 1988, Gerald Reaven(11) reintroduced the concept of syndrome X for the 
clustering of cardiovascular risk factors like hypertension, glucose intolerance, high 
triglycerides, and low HDL cholesterol concentrations. The syndrome is however, 
much older, having been already observed in 1923 by Kylin, who described the 
clustering of hypertension, hyperglycemia, and gout as a syndrome. Subsequently, 
several other metabolic abnormalities have been associated with this syndrome, 
including obesity, microalbuminuria, and abnormalities in fibrinolysis and 
coagulation. The syndrome has also been given several other names, including the 
metabolic syndrome, the insulin resistance syndrome, the plurimetabolic 
syndrome, and the deadly quartet. The name “insulin resistance syndrome” has 
been widely used and refers to insulin resistance as a common denominator of the 
syndrome. The prevalence of the metabolic syndrome has varied markedly 
between different studies, most likely because of the lack of fixed criteria for the 
definition of the syndrome. In 1998, WHO proposed a unifying definition for the 
syndrome and chose to call it the metabolic syndrome rather than the insulin 
resistance syndrome. This name was chosen primarily because it was not 
considered established that insulin resistance was the cause of all the components 
of the syndrome. 
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The metabolic syndrome (syndrome X, insulin resistance syndrome) 
consists of a constellation of metabolic abnormalities that confer increased risk of 
cardiovascular disease (CVD) and diabetes mellitus (DM). The criteria for the 
metabolic syndrome have evolved since the original definition by the World Health 
Organization in 1998, reflecting growing clinical evidence and analysis by a variety 
of consensus conferences and professional organizations. The major features of 
the metabolic syndrome include central obesity, hypertriglyceridemia, low HDL 
cholesterol, hyperglycemia, and hypertension. 
Epidemiology 
Prevalence of the metabolic syndrome varies across the globe, in part 
reflecting the age and ethnicity of the populations studied and the diagnostic 
criteria applied. In general, the prevalence of metabolic syndrome increases with 
age. The highest recorded prevalence worldwide is in Native Americans,  
with nearly 60% of women ages 45–49 and 45% of men ages 45–49 meeting 
National Cholesterol Education Program, Adult Treatment Panel III (NCEP:ATPIII) 
criteria. Based on data from the National Health and Nutrition Examination Survey 
(NHANES) III(5), the age-adjusted prevalence of the metabolic syndrome in the 
United States is 34% for men and 35% for women. In France, a 30–64-year-old 
cohort shows a <10% prevalence for each gender, although 17.5% are affected in 
the 60–64 age range. Greater industrialization worldwide is associated with rising 
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rates of obesity, which is anticipated to dramatically increase the prevalence of the 
metabolic syndrome, especially as the population ages. Moreover, the rising 
prevalence and severity of obesity in children is initiating features of the metabolic 
syndrome in a younger population.  
Risk Factors 
Overweight / Obesity  
Central adiposity is a key feature of the syndrome, reflecting the fact that the 
syndrome's prevalence is driven by the strong relationship between waist 
circumference and increasing adiposity. However, despite the importance of 
obesity, patients who are normal weight may also be insulin-resistant and have the 
syndrome.  
Sedentary Lifestyle 
Physical inactivity is a predictor of CVD events and related mortality. Many 
components of the metabolic syndrome are associated with a sedentary lifestyle, 
including increased adipose tissue (predominantly central); reduced HDL 
cholesterol; and a trend toward increased triglycerides, high blood pressure, and 
high blood glucose levels in the genetically susceptible. Compared with individuals 
who watched television or videos or used their computer <1 hour daily, those who 
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carried out these behaviors for >4hours daily have a twofold increased risk of the 
syndrome. 
 NCEP:ATPIII 2001 and IDF Criteria for the Metabolic Syndrome  
 
NCEP:ATPIII 2001 IDF Criteria for Central Adiposity 
Three or more of the following:  Waist Circumference  
Central obesity: Waist circumference >102 cm (M), 
>88 cm (F) 
Hypertriglyceridemia: Triglycerides 150 mg/dL or 
specific medication 
Low HDL cholesterol: <40 mg/dL and <50 mg/dL, 
respectively, or specific medication 
Hypertension: Blood pressure 130 mm systolic or 
85 mm diastolic or specific medication 
Fasting plasma glucose 100 mg/dL or specific 
medication or previously diagnosed type 2 diabetes 
Men  Women  Ethnicity  
94 cm 80 cm Europid, Sub-Saharan African, 
Eastern & Middle Eastern 
90 cm 80 cm South Asian, Chinese, and ethnic 
South & Central American 
85 cm 90 cm Japanese 
Two or more of the following:  
Fasting triglycerides >150 mg/dL or specific medication 
HDL cholesterol <40 mg/dL and <50 mg/dL for men and 
women, respectively, or specific medication 
Blood pressure >130 systolic or >85 mm diastolic or 
previous diagnosis or specific medication 
Fasting plasma glucose 100 mg/dL or previously 
diagnosed type 2 diabetes 
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Ageing 
The metabolic syndrome affects 44% of the U.S. population older than age 
50. A greater percentage of women older than age 50 have the syndrome than 
men. The age dependency of the syndrome's prevalence is seen in most 
populations around the world. 
 
Diabetes Mellitus  
DM is included in both the NCEP(4) and International Diabetes Foundation 
(IDF) definitions of the metabolic syndrome. It is estimated that the large majority 
(~75%) of patients with type 2 diabetes or impaired glucose tolerance (IGT) have 
the metabolic syndrome. The presence of the metabolic syndrome in these 
populations relates to a higher prevalence of CVD compared to patients with type 2 
diabetes or IGT without the syndrome. 
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Coronary Heart Disease 
The approximate prevalence of metabolic syndrome in patients with 
coronary heart disease (CHD)(7,9) is 50%, with a prevalence of 37% in patients with 
premature coronary artery disease (age 45), particularly in women. With 
appropriate cardiac rehabilitation and changes in lifestyle (e.g., nutrition, physical 
activity, weight reduction, and, in some cases, pharmacologic agents), the 
prevalence of the syndrome can be reduced. 
Lipodystrophy 
Lipodystrophic disorders in general are associated with the metabolic 
syndrome. Both genetic (e.g., Berardinelli-Seip congenital lipodystrophy, Dunnigan 
familial partial lipodystrophy) and acquired (e.g., HIV-related lipodystrophy in 
patients treated with highly active antiretroviral therapy) forms of lipodystrophy may 
give rise to severe insulin resistance and many of the metabolic syndrome's 
components. 
Etiology 
Insulin Resistance  
The most accepted and unifying hypothesis to describe the pathophysiology 
of the metabolic syndrome is insulin resistance, caused by an incompletely 
understood defect in insulin action . The onset of insulin resistance is heralded by 
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postprandial hyperinsulinemia, followed by fasting hyperinsulinemia and, 
ultimately, hyperglycemia. 
 
An early major contributor to the development of insulin resistance is an 
overabundance of circulating fatty acids. Plasma albumin-bound free fatty acids 
(FFAs) are derived predominantly from adipose tissue triglyceride stores released 
by hormone-sensitive lipase. Fatty acids are also derived through the lipolysis of 
triglyceride-rich lipoproteins in tissues by lipoprotein lipase (LPL). Insulin mediates 
both antilipolysis and the stimulation of LPL in adipose tissue. Of note, the 
inhibition of lipolysis in adipose tissue is the most sensitive pathway of insulin 
action. Thus, when insulin resistance develops, increased lipolysis produces more 
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fatty acids, which further decrease the antilipolytic effect of insulin. Excessive fatty 
acids enhance substrate availability and create insulin resistance by modifying 
downstream signaling. Fatty acids impair insulin-mediated glucose uptake and 
accumulate as triglycerides in both skeletal and cardiac muscle, whereas 
increased glucose production and triglyceride accumulation are seen in liver. 
The oxidative stress hypothesis provides unifying theory for aging and the 
predisposition to the metabolic syndrome. In studies carried out in insulin-resistant 
subjects with obesity or type 2 diabetes, in the offspring of patients with type 2 
diabetes, and in the elderly, a defect has been identified in mitochondrial oxidative 
phosphorylation, leading to the accumulation of triglycerides and related lipid 
molecules in the muscle. The accumulation of lipids in muscle is associated with 
insulin resistance. 
Increased Waist Circumference 
Waist circumference is an important component of the most recent and 
frequently applied diagnostic criteria for the metabolic syndrome. However, 
measuring waist circumference does not reliably distinguish between a large waist 
due to increases in subcutaneous adipose tissue against visceral fat; this 
distinction requires CT or MRI. With increases in visceral adipose tissue, adipose 
tissue-derived FFAs are directed to the liver. On the other hand, increases in 
abdominal subcutaneous fat release lipolysis products into the systemic circulation 
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and avoid more direct effects on hepatic metabolism. Relative increases in visceral 
versus subcutaneous adipose tissue with increasing waist circumference in Asians 
and Asian Indians may explain the greater prevalence of the syndrome in these 
populations compared to African-American men in whom subcutaneous fat 
predominates. It is also possible that visceral fat is a marker for, but not the source 
of, excess postprandial FFAs in obesity.  
Standardized instructions for the measurement of waist circumference 
 It is preferable to use a tape with a spring handle in order to control the 
tension applied on the abdomen (e.g. Gulick model). 
 Otherwise, use an unstretchable tape (avoid fabric tape) with an 
ungraduated extremity of 3-5 cm in order to properly grab the tape. 
The subject stands with his feet shoulder-width apart. The arms hang on each 
side of the body but out at an angle of about 30 degrees to allow the person taking 
the measurement to work comfortably. If this is not comfortable, alternatively 
participants can cross their arms on their shoulders in a relaxed manner. A slight 
tension should be applied to the tape (until the red mark appears) at the moment of 
the reading. 
The measurement is taken at the end of a normal expiration, while ensuring 
that the participant does not contract the abdominal muscles. (Experimenter can 
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engage conversation with patient if he is suspected to contract the abdominal 
muscles). The measurement is made twice and a third time if the difference 
between the first two measurements is greater than 5% (+/- 1 cm). The two closest 
measurements will be averaged. 
Detailed instructions 
1. Mark with a pencil bony landmarks of the right and left last rib margin. 
2. Mark with a pencil bony landmarks of the right and left iliac crest. 
3. Mark with a pencil the mid-distance between the last rib margin and the top 
of the iliac crest of the two sides. 
4. Measure mid way between the two bony points 1 and 2. 
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Dyslipidemia 
In general, FFA flux to the liver is associated with increased production of 
apoB–containing, triglyceride-rich very low density lipoproteins (VLDLs). The effect 
of insulin on this process is complex, but hypertriglyceridemia is an excellent 
marker of the insulin-resistant condition. 
The other major lipoprotein disturbance in the metabolic syndrome is a 
reduction in HDL cholesterol. This reduction is a consequence of changes in HDL 
composition and metabolism. In the presence of hypertriglyceridemia, a decrease 
in the cholesterol content of HDL is a consequence of reduced cholesteryl ester 
content of the lipoprotein core in combination with cholesteryl ester transfer 
protein–mediated alterations in triglyceride making the particle small and dense. 
This change in lipoprotein composition also results in an increased clearance of 
HDL from the circulation. The relationships of these changes in HDL to insulin 
resistance are likely indirect, occurring in concert with the changes in triglyceride-
rich lipoprotein metabolism. 
In addition to HDL, LDLs are also modified in composition. With fasting 
serum triglycerides >180 mg/dL, there is almost always a predominance of small 
dense LDLs. Small dense LDLs are thought to be more atherogenic. They may be 
toxic to the endothelium, and they are able to transit through the endothelial 
basement membrane and adhere to glycosaminoglycans. They also have 
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increased susceptibility to oxidation and are selectively bound to scavenger 
receptors on monocyte-derived macrophages. Subjects with increased small 
dense LDL particles and hypertriglyceridemia also have increased cholesterol 
content of both VLDL1 and VLDL2 subfractions. This relatively cholesterol rich 
VLDL particle may also contribute to the atherogenic risk in patients with metabolic 
syndrome. 
Glucose Intolerance 
The defects in insulin action lead to impaired suppression of glucose 
production by the liver and kidney and reduced glucose uptake and metabolism in 
insulin-sensitive tissues, i.e., muscle and adipose tissue. The relationship between 
impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) and insulin 
resistance is well supported by human, nonhuman primate, and rodent studies. To 
compensate for defects in insulin action, insulin secretion and/or clearance must 
be modified to sustain euglycemia. Ultimately, this compensatory mechanism fails, 
usually because of defects in insulin secretion, resulting in progress from IFG 
and/or IGT to DM. 
Hypertension 
The relationship between insulin resistance and hypertension is well 
established. Paradoxically, under normal physiologic conditions, insulin is a 
vasodilator with secondary effects on sodium reabsorption in the kidney. However, 
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in the setting of insulin resistance, the vasodilatory effect of insulin is lost, but the 
renal effect on sodium reabsorption is preserved. Insulin also increases the activity 
of the sympathetic nervous system, an effect that may also be preserved in the 
setting of the insulin resistance. Finally, insulin resistance is characterized by 
pathway-specific impairment in phosphatidylinositol 3-kinase signaling. In the 
endothelium, this may cause an imbalance between the production of nitric oxide 
and secretion of endothelin-1, leading to decreased blood flow. Although these 
mechanisms are provocative, when insulin action is assessed by levels of fasting 
insulin or by the Homeostasis Model Assessment (HOMA), insulin resistance 
contributes only modestly to the increased prevalence of hypertension in the 
metabolic syndrome. 
Proinflammatory Cytokines 
The increases in proinflammatory cytokines, including interleukin (IL) 1, IL-
6, IL-18, resistin, tumor necrosis factor (TNF), and C-reactive protein (CRP), reflect 
overproduction by the expanded adipose tissue mass. Adipose tissue-derived 
macrophages may be the primary source of pro-inflammatory cytokines locally and 
in the systemic circulation. It remains unclear, however, how much of the insulin 
resistance is caused by the paracrine versus endocrine effects of these cytokines. 
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Adiponectin 
Adiponectin is an anti-inflammatory cytokine produced exclusively by 
adipocytes. Adiponectin enhances insulin sensitivity and inhibits many steps in the 
inflammatory process. In the liver, adiponectin inhibits the expression of 
gluconeogenic enzymes and the rate of glucose production. In muscle, adiponectin 
increases glucose transport and enhances fatty acid oxidation, partially due to 
activation of AMP kinase. Adiponectin is reduced in the metabolic syndrome. The 
relative contribution of adiponectin deficiency and overabundance of the 
proinflammatory cytokines remains unclear.  
MYOCARDIAL INFARCTION 
Myocardial infarction is often depicted as a modern disease it was clearly 
recognized before the modern era by Morgagni in 1761. Dr.Williiam Heberden was 
the first person to describe Angina Pectoris when he described it at a meeting of 
the Royal college of Physicians in 1768. Dr.John Wall of Worchester was the first 
to ascribe angina to heart disease. An early personal description of myocardial 
infarction was given by the famous surgeon sir John Hunter who himself 
experienced what was probably a MI in 1773. The description of his subsequent 
autopsy describes the scarred areas in his heart.  Dr.John Fothergill in 1773 
described a small white cicatrix  “as big as six pence”  near the apex of the 
ventricle . In the later years four young men Jenner, Perry, Black and Burn 
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established the  “Ischaemic  theory  of  Angina” with an autopsy showing a clot in 
the coronary. It was approximately 120 years late the leaders of Medical 
Profession generally accepted the concept. The first ever description of a nonfatal 
MI comes from V.P.Obraztor and N.D.Stratzhesko of erst while U.S.S.R. in 1910.  
Americans Physicians attribute the same achievement to James B.Herrick a 
Chicago physician who in 1912 in the  journal of the American Medical  Association  
described the clinical features of sudden obstruction of the coronary arteries.  Both 
these reports belied the then current opinion that MI was universally fatal. Since 
then the Medical community has travelled far and wide into this subject. 
Coronary Atherosclerosis 
Atherosclerosis develops focally in time as well as space. Atherosclerosis 
occurs over many years, usually many decades.  The growth of atherosclerotic 
plaque probably does not occur in a smooth linear fashion but rather 
discontinuously. The clinical expression may be chronic as in stable effort angina 
or a much more dramatic incident as in myocardial infarction. Fatty streaks 
represent the initial lesion of atherosclerosis.  Lipoproteins accumulate in the 
intima of the arteries by binding to proteoglycans of extracellular  matrix.  
Sequestration within the intima seperates the lipoprotein from plasma anti-oxidants 
leading to oxidative modification. This may trigger a local inflammatory response 
signaling the subsequent steps. Next step is adhesion of mononuclear leucocytes 
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to luminal endothelium followed by migration to intima.  A number of leucocyte 
adhesion molecules, various cytokines, even modified lipoproteins mediate this 
response. Once within the intima, mononuclear phagocytes differentiate to 
macrophages and imbibes lipid and transform to lipid laden foam cells. The uptake 
of lipids by macrophages is not via the classical LDH receptor but by the 
scavenger receptor.  Some of the foam cells undergo apoptosis leading to the 
central necrotic core. The fatty streak evolves to a complicated atherosclerotic 
lesion with accumulation of smooth cells and extracellular matrix elaborated by 
smooth muscle cells of intima overlies the lipid rich core.  Plaques that are 
vulnerable to rupture have thin fibrous cap relatively large lipid cores and a high 
content of macrophages.  The sites of plaque rupture have fewer number of 
smooth muscle cells. 
Pathophysiology  – Role of Acute Plaque Rupture 
MI generally occurs when coronary blood flows decreases abruptly after 
occlusion of a coronary artery previously affected by atherosclerosis. In most 
cases mi occurs when an atherosclerotic plaque fissures, ruptures or ulcerates and 
when condition favour thrombogenesis, so that a mural thrombus is formed leading 
to coronary artery occlusion. After an initial platelet monolayer forms at the site of 
ruptured plaque various agonists (collagen, ADP, epinephrine,serotonin) promote 
platelet activation . After activation, platelets release thromboxane  A2  causing 
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further platelet activation and potential resistance to thrombolysis. Platelet 
activation also leads to conformational change to glycoprotein IIb / IIIa receptor 
causing high affinity in vWF & fibrinogen. The coagulation cascade is activated on 
exposure to tissue factor at the site of plaque rupture. Factor VII and X are 
activated ultimately leading to conversion of prothrombin to thrombin. The culprit 
artery eventually becomes occluded by a thrombus containing platelet  aggregates 
and fibrin strands. Rarely MI may be due to coronary artery occlusion by emboli, 
congenital anomalies, coronary spasm or due to systemic inflammatory disease. 
Risk factors for CAD 
Risk factors for CAD can be broadly divided into modifiable and 
nonmodifiable. The modifiable one can be divided into lipid factors and nonlipid 
factors. The nonlipid risk factors include DM, HTN, smoking, positive family history, 
gender, BMI, waist hip ratio, mental stress, while the lipid risk factors include  total 
cholesterol level,  TGL level, low level of HDL- C and high level of LDL-C.  Novel 
risk factors include CRP, homocysteine, high plasma fibrinogen, high plasminogen 
activator inhibitor,  lipoprotein(a),  lipoprotein subclass like small oxidized LDL.  It 
was Virchow  who recognized the role of lipids is atherosclerosis. Before 1950, 
there was no clear perception of the interrelationship of serum lipids, 
atherosclerosis and CAD. Since then research laboratories have made conflicting  
claims for the most useful measurement of serum lipids levels in detecting and 
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managing CAD. Emphasis has been placed in turn on the measurement of levels 
of serum cholesterol, lipoproteins and TGL.  Physical separation and 
characterization of serum lipoproteins by ultra centrifugation and electrophoresis 
resulted in two classifications system for lipoproteins based on density and 
electrophoretic mobility respectively.  
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RISK FACTORS FOR CAD 
Non-modifiable 
1. Age 
2. Family history of premature atherosclerosis* 
3. Male sex 
Modifiable, under study 
1. Alcohol intake (other than moderate) 
2. Chlamydia pneumoniae infection 
3. High CRP level 
4. High level of small, dense LDL 
5. High lipoprotein(a) level 
6. Hyperhomocysteinemia 
7. Hyperinsulinemia 
8. Hypertriglyceridemia 
9. 5-Lipoxygenase polymorphisms 
10. Low intake of fruits and vegetables 
11. Obesity or metabolic syndrome 
12. Prothrombotic states (eg, hyperfibrinogenemia, high plasminogen activator inhibitor level) 
13. Psychosocial factors (eg, type A personality, depression, anxiety, work characteristics, 
socioeconomic status) 
14. Renal insufficiency 
15. Sedentary lifestyle 
Modifiable, established 
1. Certain dyslipidemias (high total or LDL level, low HDL level, increased total-to-HDL cholesterol 
ratio) 
2. Cigarette smoking 
3. Diabetes mellitus 
4. Hypertension 
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AIM OF THE STUDY. 
1. To ascertain the prevalence of the metabolic syndrome in patients with 
acute myocardial infarction. 
2. To study the impact of the metabolic syndrome on hospital outcomes. 
3. To find out the association of each component of the metabolic syndrome 
with acute myocardial infarction. 
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MATERIALS AND METHODS 
 
SETTING: Acute Myocardial infarction patients admitted to medical wards and 
cardiac ICU at Govt Rajaji Hospital, Madurai. 
COLLABORATING DEPARTMENTS:  
1. Department of cardiology, 
Madurai medical college, 
Madurai. 
2. Department of bio – chemistry, 
Madurai medical college, 
Madurai. 
 
DESIGN OF STUDY: Prospective analytic study 
PERIOD OF STUDY: 01.04.2010 TO 30.09.2010 
SAMPLE SIZE:  100 
SELECTION OF STUDY SUBJECTS: 100 consecutive patients admitted with 
acute myocardial infarction in the department of medicine and cardiology ICU from 
01.04.2010 to 30.09.2010 formed the study group. Patients who did not satisfy the 
criteria for metabolic syndrome served as the control group. 
 Blood samples were drawn the following morning for HDL, TGL, and FBS. 
Waist circumference was measured and BP was recorded in all patients. 
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 Patients were diagnosed as having the metabolic syndrome if they had any 
three of the following five components: 
1. Abdominal obesity (waist circumference >102 cm in men and >88 cm in 
women) 
2. High triglyceride levels (≥150 mg/dl) 
3. Low HDL-C levels (<40 mg/dl in men and <50 mg/dl in women) 
4. Elevated fasting glucose levels (≥110 mg/dl) 
5. High blood pressure (treated hypertension and systolic blood 
pressure/diastolic blood pressure ≥130/85 mm Hg).  
Data was analyzed using the Student's t test and the Chi-square test. 
INCLUSION CRITERIA: 
  All patients with myocardial infarction admitted in medical wards and 
cardiology ICU were taken. 
EXCLUSION CRITERIA: 
 Patients with secondary causes affecting lipid profile were excluded., 
1. Hypothyroidism 
2. Nephrotic syndrome 
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3. Chronic kidney disease 
4. Cushing syndrome 
5. Oral contraceptives 
6. Patients not willing to participate in the study. 
ETHICAL APPROVAL: Obtained 
CONSENT: informed consent was obtained 
FINANCIAL SUPPORT: NIL 
CONFLICT OF INTEREST: NIL 
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STATISTICAL ANALYSIS 
   The information collected regarding all the selected 
cases were recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002).  
 Using this software, range, frequencies, percentages, means and  standard 
deviations  were calculated.  
Sensitivity, specificity, accuracy, positive predictive value and negative 
predictive values were calculated using the following formulae 
 
Sensitivity   =  True positive    x 100 
     True positive + False negative 
 
Specificity   =  True negative    x 100 
     False positive + True negative 
 
Positive predictive value =   True positive   x 100 
     True positive + False positive 
 
Negative predictive value =  True negative   x 100 
     True negative + False negative 
 
Accuracy   = True positive + True negative 
       N 
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A.PROFILE OF CASES STUDIED: 
  100 patients who were admitted with acute myocardial infarction 
were selected and following parameters were analysed which are as follows. 
 
TABLE 1  
QUANTITATIVE PARAMETERS 
PARAMETER RANGE MEAN SD 
AGE (in years) 33  - 70 56.1 6.4 
EF (%) 30 – 45 38.9 3.4 
DURATION OF 
STAY(days) 
2 – 15 8.3 2.6 
SBP (mmHg) 80 – 190 125.1 22.5 
DBP (mmHg) 60 – 110 80.7 11.2 
HDL (mg%) 36 – 52 43.8 4.0 
TGL (mg%) 100 – 460 166.7 70.0 
FBS (mg%) 72 – 336 123 45.0 
AC (in cm) 73 – 100 92.2 10.7 
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TABLE 2 
QUALITATIVE PARAMETERS. 
PARAMETER CASES 
NUMBER PERCENTAGE 
GENDER MALES 87 87 
FEMALES 13 13 
AREA RURAL 69 69 
URBAN 31 31 
OCCUPATION ACTIVE 35 35 
SEDENTARY 65 65 
EXERCISE YES 45 45 
NO 55 55 
SMOKING (MALES) YES 72 82.8 
NO 15 17.2 
DM YES 65 65 
NO 35 35 
HT YES 76 76 
NO 24 24 
FAMILY HISTORY YES 77 77 
NO 23 23 
DIET VEGETARIAN 33 33 
NON VEGETARIAN 67 67 
ALCOHOLS (MALES) YES 38 43.7 
NO 49 56.3 
S / N STEMI 94 94 
NSTEMI 6 6 
MI AWMI 79 79 
IWMI 21 21 
KILLIP  CLASS 1 21 21 
2 58 58 
3 18 18 
4 3 3 
THROMBOLYSIS THROMBOLYSED 91 91 
NOT  
THROMBOLYSED 
9 9 
D / A DEAD 4 4 
ALIVE 96 96 
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Among the 100 patients 87 were males and 13 were females. 69 
patients were from rural area and 31 patients were from urban area. 35 were doing 
active work and 65 were doing sedentary job. 45 were doing regular exercises and 
55 had no habit of exercising. Among the 87 male patients 72 were smokers. None 
of the females were smokers. 38 male patients were used to consume alcohol and 
none of the females took alcohol. Diabetes was pre-existing in 65 patients and 
hypertension was pre-existing in 76 patients. Family history of either  DM/ HTN/ 
CAD was present in 77 patients. 67 patients were taking mixed diet and remaining 
33 were taking vegetarian diet. STEMI occurred in 94 patients and NSTEMI 
occurred in 6 patients. AWMI occurred in 79 patients and IWMI occurred in 21 
patients. 58 patients presented in KILLIP class 2. Only 3 patients presented in 
class 3. Thrombolysis was done in 91 patients and in the remaining 9 patients it 
was not done due to contraindications. Among the 100 patients 4 of them died 
during the hospital stay. 
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TABLE 3 
PREVALENCE OF METABOLIC SYNDROME 
METABOLIC 
SYNDROME 
CASES 
NUMBER PERCENTAGE 
POSITIVE 32 32 
NEGATIVE 68 68 
TOTAL 100 100 
 
Among the 100 patients 32 patients satisfied the criteria for metabolic 
syndrome and taken as study subjects and the remaining 78 patients formed the 
internal control group. Further comparisons were made between these two groups. 
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TABLE 4  
OUTCOME IN METABOLIC SYNDROME 
 
METABOLIC 
SYNDROME 
OUTCOME 
ALIVE DEAD 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
POSITIVE (32 ) 29 90.6 3 9.4 
NEGATIVE(68 ) 67 98.5 1 1.5 
‘ p’ 0.0952 
NOT SINIFICANT 
 
Among the 32 patient in the study group 3(9.4%) patients died and among 
the 78 patients in the control group 1(1.5%) patient died and the ‘p’ value was 
0.0952 which was statistically not significant.  
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TABLE 5 
 ASSOCIATION BETWEEN FIVE COMPONENTS OF METABOLIC SYNDROME 
 
COMPONENTS OF 
METABOLIC SYNDROME 
TOTAL 
CASE 
METABOLIC SYNDROME ‘p’ 
POSITIVE NEGATIVE 
B . P POSITIVE 80 29 36.3 51 63.8 0.1201 (NOT 
SIGNIFICANT) 
NEGATIVE 20 3 15 17 85 
HDL ABNORMAL 21 15 71.4 6 28.6 0.0001 (SIGNIFICANT) 
NORMAL 79 17 21.5 62 78.5 
TGL ABNORMAL 49 30 61.2 19 38.8 0.0001(SIGNIFICANT) 
NORMAL 51 2 3.9 49 96.1 
FBS ABNORMAL 36 29 80.6 7 19.4 0.0001(SIGNIFICANT 
NORMAL 64 3 4.7 61 95.3 
AC ABNORMAL 27 24 88.9 3 11.1 0.0001(SIGNIFICANT) 
NORMAL 73 8 11 65 89 
 
The association between BP and metabolic syndrome was not significant 
statistically as the ‘p’ value was 0.1201. There was significant statistical 
association between HDL, TGL, FBS, AC and metabolic syndrome  (p value – 
0.0001). 
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TABLE 6 
 COMPARATIVE EFFICACY OF THE 5 COMPONENTS. 
COMPONENT 
OF     
METABOLIC 
SYNDROME 
TRUE 
+VE 
FALSE 
+VE 
TRUE 
-VE 
FALSE 
-VE 
SENSITIVIT
Y 
SPECIFICITY ACCURACY PPV NPV 
BP 29 51 17 3 91 25 46 36 85 
HDL 15 6 62 17 47 91 77 71 78 
TGL 30 19 49 2 94 72 79 61 91 
FBS 29 7 61 3 91 90 90 81 95 
AC 24 3 65 8 75 96 89 89 80 
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Among the 5 components abdominal circumference had high specificity 
(96%) followed by HDL level (91%). TGL had high sensitivity (94%). Abdominal 
circumference also had high positive predictive value (89%). 
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TABLE 7  
DURATION OF HOSPITAL STAY 
METABOLIC SYNDROME HOSPITAL STAY 
RANGE MEAN SD 
POSITIVE 2 – 15 10.6 3.5 
NEGATIVE 10 – 12 7.3 0.9 
 
‘ p ‘ 
 
0.0001 (SIGNIFICANT) 
 
The mean duration of hospital stay was prolonged in patients with metabolic 
syndrome (10.6 days) compared to the control group (7.3 days). The ‘p’ value was 
0.0001 which was statistically significant. 
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TABLE 8  
EJECTION FRACTION AND METABOLIC SYNDROME. 
EF METABOLIC SYNDROME 
POSITIVE NEGATIVE 
RANGE 30 – 42 34 – 45 
MEAN 36.0 40.3 
SD 3.6 2.2 
 
‘ p ‘ 
 
0.0001 (SIGNIFICANT) 
 
Mean ejection fraction was low in the study group (36%) compared to the 
control group (40.3). The ‘p’ value was 0.0001 which was statistically significant.  
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TABLE 9  
 KILLIP CLASS AND METABOLIC SYNDROME 
KILLIP CLASS METABOLIC SYNDROME 
POSITIVE NEGATIVE 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
1 (21) - - 21 100 
2 (58) 20 34.5 38 65.5 
3 (18 ) 9 50 9 50 
4 (3) 3 100 - - 
 
Patients in the study group presented in Killip class 2 – 4. None were in 
killip class 1. Three  patients in the study group presented in Killip class 4.  
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TABLE 10   
STEMI / NSTEMI AND METABOLIC SYNDROME. 
STEMI METABOLIC SYNDROME 
POSITIVE NEGATIVE 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
STEMI (94) 31 33 63 67 
NSTEMI (6) 1 16.7 5 83.3 
 
‘ p ‘ 
 
0.3716 (NOT SIGNIFICANT) 
 
STEMI occurred in 33% of study group and 67% of control group. This was 
not statistically significant (p value – 0.3716). 
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TABLE 11  
 THROMBOLYSIS AND METABOLIC SYNDROME. 
METABOLIC 
SYNDROME 
THROMBOLYSIS 
YES NO 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
POSITIVE (32) 29 90.6 3 9.4 
NEGATIVE (68) 62 91.6 6 8.8 
 
‘ p ‘ 
 
0.597 (NOT SIGNIFICANT) 
 
Thrombolysis was done in 90.6% of study group patients and in 91.6% of 
control group patients. This was not statistically significant as the ‘p’ value was 
0.597. 
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TABLE 12  
 AGE AND METABOLIC SYNDROME. 
 
 
 
 
 
It was found that metabolic syndrome patients were slightly aged (mean 
57.6 years) compared to control group (mean 55.3 years), but the difference was 
not statistically significant.  
 
METABOLIC 
SYNDROME 
AGE IN YEARS 
RANGE MEAN SD 
POSITIVE 45 – 70 57.6 5.2 
NEGATIVE 33  - 68 55.3 6.8 
 
‘ p ‘ 
 
0.1812 (NOT SIGNIFICANT) 
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TABLE 13  
GENDER AND METABOLIC SYNDROME. 
SEX METABOLIC SYNDROME 
POSITIVE NEGATIVE 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
MALES(87) 28 32.2 59 67.8 
FEMALES(13) 4 30.8 9 69.2 
 
‘ p ‘ 
 
0.5962 (NOT SIGNIFICANT) 
 
It was found that metabolic syndrome was more prevalent in males (32.2%) 
compared to females (30.8%), but the difference was not statistically significant. 
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TABLE 14   
AREA OF RESIDENCE AND METABOLIC SYNDROME. 
RESIDENCE METABOLIC SYNDROME 
POSITIVE NEGATIVE 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
RURAL (9) 20 29 49 71 
URBAN (31) 12 38.7 19 61.3 
 
‘ p ‘ 
 
0.464 (NOT SIGNIFICANT) 
 
 
Metabolic syndrome was slightly more prevalent in patients from urban area 
(38.7) compared to patients from rural area (29%), but the difference is not 
statistically significant (p value – 0.464). 
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TABLE 15 
 OCCUPATION AND METABOLIC SYNDROME. 
OCCUPATION METABOLIC SYNDROME 
POSITIVE NEGATIVE 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
ACTIVE(35) 5 14.3 30 85.7 
SEDANTARY (65) 27 41.5 38 58.5 
 
‘ p ‘ 
 
0.0104  SIGNIFICANT 
 
Among patients with metabolic syndrome 14.3% were active workers and 
among the control group 85.7%  were active workers, the difference being 
statistically significant (p value – 0.0104).  
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TABLE 16  
EXERCISE AND METABOLIC SYNDROME. 
EXERCISE METABOLIC SYNDROME 
POSITIVE NEGATIVE 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
YES (45) 7 15.6 38 84.4 
NO (55) 25 45.5 30 54.5 
 
‘ p ‘ 
 
0.0029 (SIGNIFICANT) 
 
Among the study group patients, 15.6% were doing regular exercise and 
among the control group 84.4% were doing regular exercise. The difference is 
statistically significant (p value 0.0029).  
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TABLE 17  
 FAMILY HISTORY AND METABOLIC SYNDROME. 
FAMILY HISTORY METABOLIC SYNDROME 
POSITIVE NEGATIVE 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
YES (77) 28 36.4 49 63.6 
NO (23) 4 17.4 19 82.6 
 
‘ p ‘ 
 
0.1451 (NOT SIGNIFICANT) 
 
 
Family history was positive in 36.4% of patients in study group and 63.6% 
of patients in control group, the difference being not statistically significant         
(p value – 0.1451). 
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TABLE 18  
SMOKING AND METABOLIC SYNDROME 
SMOKING METABOLIC SYNDROME 
YES NO 
NUMBER PERCENTAGE NUMBER PERCENTAGE 
SMOKERS 26 92.8 46 77.9 
NON SMOKERS 2 7.2 13 22.1 
 
‘ p ‘ 
 
0.0738  NOT SIGNIFICANT 
 
Smokers were present in both groups and there was a slight increased 
prevalence of the syndrome in smokers, but this was not statistically significant (‘p’ 
value – 0.0738). 
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DISCUSSION. 
100 proven cases of acute myocardial infarction who were admitted to the 
medical ward and cardiac intensive care unit were selected for analyzing the 
prevalence of metabolic syndrome. All of them satisfied the inclusion criteria. 
All patients were subjected to detailed clinical history and examination. BP 
was recorded from all patients.12 lead ECG was done whenever indicated. ECHO 
was done for all patients. 
Abdominal circumference of all patients were measured in standing position 
at a point midway between lower most point of costal margin and upper most point 
of iliac crest. In a few moribund patients who could not stand, measurement was 
taken in supine position. 
Blood sample was taken for analysis of blood sugar, urea, creatinine and 
electrolytes on the first day and for fasting blood sugar and lipid profile on the 
morning of day 3. 
In our study the 32 patients who satisfied the criteria for metabolic 
syndrome were taken as study subjects and the remaining 68 patients who had no 
metabolic syndrome served as the control group. 
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COMPARATIVE ANALYSIS 
 There is very limited information about the relationship of the metabolic 
syndrome with acute MI, particularly in South-East Asia, although western studies 
suggest that it is very commonly associated with coronary artery disease. A similar 
study was conducted by Pandey et al, at Nepal (2). 
 The prevalence of metabolic syndrome in acute MI patients in our study 
was 32% whereas in Pandey et al study it was 26.19%. but the prevalence of 
metabolic syndrome in the general population was 18.3% in one study conducted 
by Prabhdeep et al at Chennai (Japi June 2010). In a north Indian study the 
prevalence of metabolic syndrome in general population was 24.9%. the reason for 
a slightly higher prevalence in our study could be due to highly selected group of 
acutely ill patients. 
 The mean age of patients with metabolic syndrome is 57.6 years and about 
90.6% of the study group patients were above 50 years of age. In Pandey et al 
86% of patients were above 50 years. 
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COMPARISON OF THE  TWO GROUPS 
PARAMETERS STUDY GROUP CONTROL GROUP ‘p’ VALUE 
Mean age 57.6 55.3 0.1812 (not significant) 
Gender 
 
Males  32.2% 67.8% 0.5962 (not significant) 
Females  30.8% 69.2% 
Area  Rural  29% 71% 0.464 (not significant) 
Urban  38.7% 61.3% 
Occupation  Active  14.3% 85.7% 0.0104 (significant) 
Sedentary  41.5% 58.5% 
Exercise  Yes  15.6% 84.4% 0.0029 (significant) 
No  45.5% 54.5% 
Family 
history  
Yes  36.4% 63.6% 0.1451 (not significant) 
No  17.4% 82.6% 
Smoking Yes 92.8% 77.9% 0.0738 (not significant) 
No 7.2% 22.1% 
MI STEMI 33% 67% 0.3716 (not significant) 
NSTEMI 16.7% 83.3% 
Duration of stay (days)    10.6 7.3 0.0001 (significant) 
EF (%) 36 40.3 0.0001 (significant) 
BP >130/85 36.3% 63.8% 0.1201 (not significant) 
<130/85 15% 85% 
HDL Low 71.4% 28.6% 0.0001 (significant) 
High 21.5% 78.5% 
TGL >150 61.2% 38.8% 0.0001 (significant) 
<150 3.9% 96.1% 
FBS >110 80.6% 19.4% 0.0001 (significant) 
<110 4.7% 95.3% 
AC High 88.9% 11.1% 0.0001 (significant) 
Low 11% 89% 
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In our study, prevalence of metabolic syndrome is slightly higher in males 
(32.2%) compared to females (30.8%). Whereas, in Pandey et al study, prevalence 
was higher among females. A similar high prevalence among females has also 
been reported by Zellar et al (9). 
 In our study, in-hospital fatality is more among those with the metabolic 
syndrome (3/32) than those without the syndrome (1/68). In Pandey et al study 
similar results were obtained – in hospital fatality rate was 5/22 in patients with 
metabolic syndrome and 3/62 in the control group.   Another study has also 
reported that the metabolic syndrome was associated with an increased case 
fatality rate. However, after adjusting for the major determinants of mortality in AMI, 
the metabolic syndrome was not seen to be an independent predictor of this. 
Among the individual components of the metabolic syndrome, we found that 
increased abdominal circumference had the highest positive predictive value (89%) 
and this was followed by fasting blood glucose (81%); blood pressure had the least 
positive predictive value (36%). This indicates that obesity is  associated with 
higher morbidity and may predispose to a higher mortality. In Pandey et al study, 
raised triglyceride levels had the highest positive predictive value (62%), followed 
by fasting blood sugar (55%) like our study. Blood pressure had least positive 
predictive value as in our study. As reported by a previous study, at long-term 
follow up, hypertension is only a modest predictor of death.  
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Duration of hospital stay is prolonged in patients in the study group (10.6 
days) compared to 7.3 days in the control group. Pandey et al also reported a 
prolongation of hospital stay in their patients with metabolic syndrome. This may 
be due to severity of illness based on Killip class and low ejection fraction in the 
study group. Patients with metabolic syndrome presented with higher Killip class (> 
2). None of the patients in the study group presented in class 1. Also the mean EF 
is reduced in the study group patients (36%) compare to control group (40.3%). 
Among the study group only 15.6% were doing regular exercise and among 
the control group 84.4% were doing regular exercise. The difference is statistically 
significant. This could be the reason for the increased morbidity in the study group. 
Smokers were present in both the groups. Smoking itself is an important 
risk factor for myocardial infarction, but there was no statistical difference between 
the two groups. So, smoking does not increase the morbidity associated with 
metabolic syndrome in myocardial infarction patients. 
Among the study group only 14.3% were doing active job and among the 
control group 85.7% were doing active job. The difference is statistically significant. 
Family history was present in 36.4% of study subjects and 63.6% of control 
subjects and the difference was not significant. This indicates that apart from family 
history, lack of exercise and sedentary job plays a role in development of metabolic 
syndrome. 
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As the prevalence of the metabolic syndrome is high worldwide and 
increasing day by day due to sedentary lifestyles, the findings of the present study 
has important implications for clinical practice. Emphasis must be placed on the 
intake of balanced diet and control of blood lipid levels, particularly that of 
triglycerides. Since elevated fasting blood glucose has such a high predictive value 
in acute MI, there must be a careful search for deranged carbohydrate metabolism 
in all cases. 
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SUMMARY 
The study “prevalence of metabolic syndrome in patients with acute 
myocardial infarction” was conducted in 100 acute MI patients admitted in medical 
wards and cardiac ICU at the Government Rajaji hospital, Madurai. 
 All the 100 patients satisfied the inclusion criteria and underwent 
various investigations – ECG, blood sugar, urea, creatinine, lipid profile and 
echocardiogram. Prevalence of metabolic syndrome was assessed in them by 
using NCEP ATP III criteria. The patients who satisfied the criteria formed the 
study group and those who did not formed the control group. Various parameters 
were compared between the two groups. 
 The in hospital mortality rate was high in the study group and 
duration of hospital stay was also high in the study group compared to the control 
group. 
 The study group had higher percentage of patients with sedentary 
job and physical inactivity. 
 The study showed increased prevalence of metabolic syndrome in 
acute MI patients compared to general population when compared to other studies. 
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CONCLUSION 
The following conclusions were derived from our study, 
1. The prevalence of metabolic syndrome is 32% among patients admitted 
with acute MI. 
2. Duration of hospital stay is prolonged in patients with metabolic syndrome 
(10.6 days vs 7.3 days). 
3. Abdominal circumference (AC) has highest positive predictive value (89%) 
followed by fasting blood sugar (FBS) which has (81%), followed by 
triglyceride (TGL) level which has (61%) positive predictive value. 
4. BP has the least positive predictive value of 36%. 
5. Mean EF is low in the study group (36%) compared to control group 
(40.3%). 
6. Study group had high rate of sedentary job (41.5%) and high rate of 
physical inactivity (45.5%). 
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GLOSSARY 
 
AC    Abdominal circumference 
BP    Blood pressure 
CAD    Coronary artery disease 
DM    Diabetes mellitus 
EF    Ejection fraction 
FBS    Fasting blood sugar 
HTN    Hypertension 
HDL    High density lipoprotein 
LDL    Low density lipoprotein 
MI    Myocardial infarction 
MS    Metabolic syndrome 
NCEP –ATPIII National cholesterol education programme – 
adult treatment  panel III. 
NPV Negative predictive value 
NSTEMI Non ST elevation myocardial infarction 
PPV Positive predictive value 
STEMI ST elevation myocardial infarction 
TGL  Triglycerides 
vWF  Von Willibrand factor 
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S.no IP No Age Sex Area Occ Exer Smok Alco DM HT F/H V/NV S/N MI EF KILP Thromb Dura D/A BP HDL TGL FBS AC MS 
1 254367 38 M R A Y N N N N Y NV S A 40 3 Y 7 A 120/80 38 300 80 88 2 
2 254376 54 M R S N Y Y N N Y NV S A 38 3 Y 10 A 130/90 44 140 200 104 3 
3 254373 60 M R A N Y Y N N Y NV S A 36 3 Y 7 A 130/90 36 250 73 104 4 
4 254372 60 M U S N Y N Y Y Y NV S I 30 4 Y 2 D 130/100 40 180 130 104 4 
5 254438 47 M R A Y Y Y N Y Y NV S A 40 3 Y 7 A 130/90 41 240 72 83 2 
6 254444 60 M R S N Y Y Y Y Y NV S A 30 4 N 2 D 80/60 45 400 320 110 4 
7 254448 45 M R S N Y Y N N Y NV S I 36 3 Y 7 A 130/90 44 180 158 73 3 
8 254451 53 M R A Y Y Y Y Y Y NV N A 40 3 N 10 A 130/90 46 160 99 100 2 
9 254450 52 F R S N N N Y Y Y V S A 42 2 Y 7 A 140/100 48 460 336 76 4 
10 254620 50 M R S N Y Y N Y Y NV S A 38 3 Y 10 A 130/90 44 215 204 98 3 
11 198354 70 M U S N Y Y Y Y Y NV S I 38 2 Y 10 A 140/90 43 250 153 96 3 
12 227233 52 M R A Y Y Y N N Y NV S A 38 3 N 10 A 80/60 51 240 172 100 2 
13 254736 55 F R S N N N Y Y Y NV S A 40 3 Y 7 A 140/90 50 120 93 86 1 
14 254740 57 M R A N Y N Y Y Y V S A 42 3 Y 7 A 120/80 42 110 100 96 2 
15 255732 58 M R A N N N Y Y Y NV S A 42 2 Y 10 A 120/80 44 115 100 100 2 
16 255781 49 F U S Y N N Y N Y V S A 45 2 Y 10 A 130/90 52 115 100 80 1 
17 255750 55 M R A Y Y Y N Y Y NV S A 40 2 Y 7 A 140/90 45 115 102 95 2 
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S.no IP No Age Sex Area Occ Exer Smok Alcoh DM HT F/H V/NV S/N MI EF KILP Thromb Dura D/A BP HDL TGL FBS AC MS 
18 255741 33 M R S N Y Y N N Y NV N I 38 3 N 12 A 110/70 45 100 90 80 0 
19 255065 67 M U S N Y Y Y Y Y NV S A 40 3 Y 10 A 140/90 40 125 124 106 3 
20 255128 55 M R S N Y Y N Y Y NV S A 36 3 Y 12 A 170/100 44 160 190 110 4 
21 255320 52 M R A Y Y Y N N N NV S I 40 3 Y 7 A 100/80 44 180 86 100 1 
22 255346 62 M R A N Y Y Y Y Y NV S A 38 2 Y 7 A 120/80 47 100 96 90 1 
23 255434 65 M U A N Y N Y Y N V S A 45 2 Y 7 D 120/80 47 110 90 90 1 
24 255476 60 F R A N N N Y Y N V S A 40 2 Y 7 A 110/70 51 120 100 96 2 
25 255523 54 M U S N Y N N Y N NV S A 42 2 Y 12 A 160/90 36 200 120 110 5 
26 255579 52 M R A N Y N Y N N V S A 42 1 Y 7 A 110/70 40 121 86 90 0 
27 255638 52 M R S N N N Y N N NV S A 38 2 Y 12 A 110/70 36 300 200 108 4 
28 255674 60 M R A N Y Y N Y Y V S I 38 2 Y 7 A 150/90 50 110 100 90 1 
29 255689 62 F R A Y N N Y Y N V S A 40 2 Y 7 A 110/70 48 110 100 86 2 
30 255690 68 M R A Y Y N Y Y Y NV S A 42 1 Y 7 A 110/70 40 120 100 90 1 
31 255743 60 M R A N Y N Y Y N NV S A 40 2 Y 12 A 150/90 40 200 160 110 4 
32 255799 62 F R A N N N N Y N V S A 42 1 Y 7 A 120/80 50 110 100 86 1 
33 255992 57 F R S Y N N N Y Y V N A 40 1 N 7 A 110/70 46 108 86 84 2 
34 255999 61 M R A Y Y Y Y Y Y V S I 40 2 Y 7 A 120/80 42 110 108 90 1 
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S.no IP No Age Sex Area Occ Exer Smok Alcoh DM HT F/H V/NV S/N MI EF KILP Thromb Dura D/A BP HDL TGL FBS AC MS 
35 256010 54 M R S N Y N N N N V S A 40 2 Y 7 A 110/70 46 110 100 90 0 
36 256034 60 M R S N Y Y Y Y Y NV S A 32 3 Y 12 A 160/100 38 310 170 108 5 
37 256067 52 M R A Y Y N N Y N V S A 42 1 Y 7 A 110/70 46 110 90 86 1 
38 256098 60 F R S Y N N Y Y Y V S I 42 1 Y 7 A 110/70 40 110 106 85 2 
39 256167 61 M U S Y Y N Y Y Y V S A 40 1 Y 7 A 110/70 50 110 96 80 1 
40 256198 61 M U S N Y Y Y Y Y NV S I 36 2 Y 12 A 160/90 36 210 180 110 5 
41 256256 40 M R A N N N N N N NV S A 40 1 Y 7 A 110/70 46 120 108 110 1 
42 256287 60 M R S Y Y Y Y Y Y NV S A 38 2 Y 7 A 110/80 46 110 100 90 1 
43 256343 58 M R S N Y N Y Y N NV S A 40 2 Y 7 A 110/70 48 110 90 90 1 
44 256456 62 M R S N Y N Y Y Y V S A 42 2 Y 7 A 110/80 48 112 86 80 1 
45 256543 60 M U A N Y Y Y Y Y NV N A 36 3 N 12 A 160/100 36 310 148 108 5 
46 256578 63 M R S N Y N Y Y Y V S I 38 3 Y 7 A 120/80 42 111 90 86 1 
47 256669 57 M R S Y Y Y Y Y Y NV S A 40 2 Y 7 A 110/80 46 116 90 80 1 
48 256700 57 M R S N Y N Y Y Y NV S A 40 2 Y 7 A 110/74 48 108 101 81 1 
49 256745 59 M U S Y Y N Y Y Y V S A 42 1 Y 7 A 110/80 46 114 102 81 1 
50 256750 60 M U A Y Y Y N Y Y NV S A 45 1 Y 7 A 168/80 46 116 86 80 1 
51 256788 54 F R A Y N N N N Y V S I 45 1 Y 7 A 120/70 48 112 100 90 1 
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S.no IP No Age Sex Area Occ Exer Smok Alcoh DM HT F/H V/NV S/N MI EF KILP Thromb Dura D/A BP HDL TGL FBS AC MS 
52 256832 60 M R S Y N Y N Y Y NV S A 40 2 Y 7 A 110/70 49 108 87 80 1 
53 256846 49 M U S N Y N N Y Y NV S A 40 2 Y 10 A 140/100 40 210 140 108 4 
54 256877 61 M U S N Y N Y Y Y NV S A 38 2 Y 12 A 120/80 36 260 108 108 3 
55 256901 52 M U S N Y N Y Y Y NV S A 42 1 Y 7 A 110/70 42 110 91 80 1 
56 256954 61 M R S Y N N Y Y N NV N A 42 2 N 7 A 110/70 48 170 101 80 2 
57 256993 54 M U S N Y N Y Y Y NV S A 40 2 Y 7 A 110/70 46 170 102 80 2 
58 257045 61 M R S N Y Y Y Y Y NV S A 30 4 N 3 D 80/60 40 300 200 108 4 
59 257074 60 M R A N Y N N N Y NV S A 42 2 Y 7 A 108/80 47 110 84 80 0 
60 257145 49 M U A Y Y N N Y Y V S A 42 2 Y 7 A 110/80 48 120 110 100 1 
61 257245 48 M U S N Y N N Y Y V S A 45 2 Y 7 A 108/70 46 170 108 86 2 
62 257323 46 M R A Y N N N Y Y V S I 40 2 Y 7 A 110/70 46 160 102 80 2 
63 257368 48 M R A Y Y N N N N NV S A 42 2 Y 7 A 110/80 46 170 110 100 2 
64 257399 57 M R S N Y N Y Y Y NV S A 42 2 Y 7 A 110/70 42 180 104 80 2 
65 257412 61 M R A N Y N Y Y Y V S A 42 1 Y 7 A 110/70 45 140 125 100 2 
66 257450 63 M R A Y N Y Y Y Y NV S A 38 2 Y 7 A 120/80 48 170 101 80 2 
67 257488 53 F U S Y N N Y N Y V S A 36 2 Y 7 A 110/80 41 140 90 80 0 
68 257550 48 M R S Y Y N Y Y Y V S A 40 2 Y 7 A 110/70 45 130 86 80 1 
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S.no IP No Age Sex Area Occ Exer Smok Alcoh DM HT F/H V/NV S/N MI EF KILP Thromb Dura D/A BP HDL TGL FBS AC MS 
69 257656 50 M R S Y N Y Y Y N V S A 38 1 Y 7 A 110/70 42 160 96 80 2 
70 257690 49 M R A N Y N Y Y Y V S A 40 2 Y 7 A 120/80 44 160 101 80 2 
71 257765 62 M R A N Y N Y Y Y NV S A 40 1 Y 7 A 110/70 44 130 101 80 1 
72 257798 57 M R S N Y N Y Y Y NV S A 30 3 Y 15 A 160/90 38 300 200 96 4 
73 257807 60 M R S Y Y Y Y Y Y V S A 38 2 Y 12 A 120/80 42 320 180 110 4 
74 257987 56 M R S Y Y Y Y N Y V S A 36 2 Y 12 A 120/80 40 316 180 110 3 
75 257996 67 M R S Y N Y Y Y Y NV S A 40 2 Y 7 A 130/90 45 160 100 80 2 
76 258110 60 F U S N N N Y Y Y V S A 36 2 Y 12 A 160/100 42 300 160 88 3 
77 258156 58 M R A N Y Y Y Y Y NV S I 38 2 Y 7 A 110/70 46 120 100 86 1 
78 258223 51 M R S Y N N Y Y Y NV S A 38 2 Y 12 A 160/90 48 190 140 86 3 
79 258324 48 M U S Y Y N Y N Y NV S I 40 2 Y 7 A 110/70 42 160 100 89 1 
80 258390 54 M U S Y N Y N Y Y NV S A 36 2 Y 7 A 110/70 44 140 100 82 1 
81 258426 53 M U S Y Y N Y N Y NV S A 38 1 Y 7 A 110/80 44 160 102 96 1 
82 258467 42 M U S N Y N Y N Y NV S A 42 2 Y 7 A 120/80 46 140 180 86 1 
83 258499 61 M R A Y Y Y Y Y Y NV S I 30 2 Y 12 A 180/100 40 200 180 100 4 
84 258523 60 M R S Y Y N N Y N V S A 42 2 Y 7 A 150/80 46 140 101 87 1 
85 258587 58 M R S N Y Y Y Y Y NV S A 40 1 Y 7 A 140/90 44 116 140 90 1 
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S.no IP No Age Sex Area Occ Exer Smok Alcoh DM HT F/H V/NV S/N MI EF KILP Thromb Dura D/A BP HDL TGL FBS AC MS 
86 258623 55 M U S N N Y N Y Y NV S A 36 2 Y 7 A 160/90 46 110 102 89 1 
87 258650 63 M R S Y N N Y N N NV S A 34 2 Y 7 A 110/70 46 160 180 90 2 
88 258667 59 M R S Y Y Y Y Y Y NV S I 30 2 Y 12 A 170/100 38 170 140 110 5 
89 258756 60 F U S Y N N Y Y Y NV S I 38 2 Y 10 A 160/90 40 160 120 90 4 
90 258789 58 M U S Y Y N N Y N NV S A 40 1 Y 7 A 140/100 44 110 90 86 1 
91 258823 48 M R S N Y N Y N N NV S A 38 1 Y 7 A 110/70 46 115 140 90 1 
92 258890 56 M U S Y Y N N Y Y V S A 40 1 Y 7 A 110/70 40 110 86 90 1 
93 258945 60 M R S N Y Y N N N NV S A 38 2 Y 7 A 110/70 38 190 90 104 3 
94 259016 53 M R S Y Y N Y N Y NV S I 40 2 Y 7 A 120/80 46 116 150 90 1 
95 259212 52 M U S N Y N N Y Y NV S A 36 2 Y 15 A 110/70 36 200 180 108 5 
96 259378 60 M U S N N N Y Y N NV N A 40 1 N 7 A 106/70 46 110 87 86 1 
97 259456 53 M U S Y Y N N Y N NV S I 38 2 Y 7 A 120/80 40 180 110 90 2 
98 259498 55 M U A N Y N Y Y Y V S A 36 2 Y 15 A 180/110 40 190 160 108 5 
99 259557 61 F R S N N N Y Y Y NV S I 34 2 Y 15 A 190/100 38 160 140 100 5 
100 259592 60 M R S Y Y Y Y Y Y NV S I 36 2 Y 15 A 170/100 44 186 140 110 4 
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AREA:  R – RURAL U – URBAN 
OCCUPATION (OCC): A – ACTIVE S – SEDANTARY 
EXERCISE (EXER): Y – YES  N – NO 
SMOKING (SMOK): Y – YES  N – NO 
ALCOHOL (ALCO): Y – YES  N – NO 
DIABETES (DM):     Y – YES  N – NO 
HYPERTENSION (HT):      Y – YES N – NO 
FAMILY HISTORY (F/H):  Y – YES  N – NO 
DIET (V/NV):  V –VEG  NV – NON VEG 
 S/N:   S –STEMI N – NSTEMI 
MI:   A – AWMI I – IWMI 
EF:   EJECTION FRACTION 
KLIP:   KILLIP CLASS 
THROMBOLYSIS (THROMB):  T – THROMBOLYSED N – NOT THROMBOLYSED 
DURA - DURATION OF STAY 
D/A – DEAD / ALIVE 
MS –METABOLIC SCORE. 
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PROFORMA 
PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH ACUTE MYOCARDIAL 
INFARCTION AND ITS IMPACT ON HOSPITAL OUTCOME. 
 
PT  NO:       DATE:           PLACE: 
 
PT NAME:      AGE:    SEX: 
 
ADDRESS: 
 
OCCUPATION: 
 
PRESENT HISTORY: 
 
PAST HISTORY:       DM  HTN   CAD  CKD   CVA        COPD 
 
FAMILY HISTORY:   DM  HTN   CAD  CKD  OBESITY 
 
PERSONAL  HISTORY:      SMOKING: NO. OF CIGARRETE  PACKS PER DAY –  
     NO. OF YEARS OF SMOKING –  
     PACK YEARS –   
   TOBACCO CHEWING: 
ALCOHOLIC: NO.OF YEARS – 
  FREQUENCY  -  
 
MENSTURAL HISTORY: PRE MENOPAUSAL  POST MENOPAUSAL 
 
DIETARY HISTORY: VEG  MIXED 
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EXAMINATION: 
PR –  
BP –  
KILLIP CLASS –  
 
ECG FINDINGS: 
 
ECHO FINDIGS:        EF: 
 
TREATMENT GIVEN: 
 
DURATION OF HOSPITAL  STAY: 
 
METABOLIC SYNDROME:     ( /5)    OTHER INVESTIGATIONS: 
     
     
 
                 
 
 
         
 
FOLLOW – UP: 
 
 
 
 
BP: 
 
 
HDL: 
 
 
TGL: 
 
 
FBS: 
 
 
ABD CIRC: 
 
 
